References
- Wolf J, Siegel D, Goldschmidt H, . A phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012;53: In press.
- Richardson P, Mitsiades C, Colson K, . Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49:502–507.
- Niesvizky R, Ely S, Mark T, . Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011;117:336–342.
- Piekarz RL, Frye R, Prince HM, . Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827–5834.
- Coiffier B, Pro B, Prince HM, . Results from a pivotal, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma following prior systemic therapy. J Clin Oncol 2012; 1820–1823.
- Kirschbaum M, Frankel P, Popplewell L, . Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198–1203.
- Younes A, Sureda A, Ben-Yehuda D, . Panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous stem cell transplant: results of a phase II study. J Clin Oncol 2012; Jan 23: PMID: 22271479 [Epub ahead of print].
- Ocio EM, San Miguel JF. The DAC system and associations with multiple myeloma. Invest New Drugs 2010;28(Suppl. 1):S28–S35.
- Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28(Suppl. 1):S3–S20.
- Harrison SJ, Quach H, Link E, . A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011;118:6274–6283.
- Knop S. From the observation DAC: romidepsin revisited. Blood 2011;118:6231–6232.
- Dimopoulos MA, Jagannath S, Yoon S-S, . Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 Trial. Blood 2011;118(Suppl. 1): Abstract 811.
- Richardson PG, Alsina M, Weber DM, . Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). Blood 2011;118 (Suppl. 1): Abstract 814.
- San-Miguel JF, de Moraes Hungria VT, Yoon S-S, . Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. Blood 2011;118(Suppl. 1): Abstract 3976.